ALNY - Alnylam Pharma lifts 2021 guidance as revenue growth accelerates

Alnylam Pharmaceuticals (NASDAQ:ALNY) exceeded analyst expectations for Q2 2021 as its revenue for the quarter more than doubled from the previous year prompting the management to raise the guidance for 2021. The company reported $220.6M in revenue in Q2 2021 with ~112% YoY growth driven by ONPATTRO sales which generated $114M in revenue with ~12% YoY growth. In Q1 2021, Alnylam posted ~$177.6M in revenue with ~79% YoY growth. The company said, there were 1,725 patients who were under commercial ONPATTRO treatment worldwide as of the end of the quarter compared to 1,500 patients in the previous quarter-end. While net product revenue increased ~107% YoY to $160.8M, the net revenue from collaborations rose ~125% YoY to $59.4M. Meanwhile, GAAP net loss narrowed by ~5.8% YoY to $189.6M while cash and equivalents reached $1.90B compared to $1.87B in the previous year-end. Among notable milestones this year, Alnylam expects topline results for 18-month

For further details see:

Alnylam Pharma lifts 2021 guidance as revenue growth accelerates